Home » Newsletters » BioWorld

BioWorld

Jan. 27, 1992

View Archived Issues

BLOOD VIRUS ELIMINATION PROJECT ABORTED

BIOSYS FILES FOR 2.3 MILLION-SHARE IPO

HYBRIDON PATENT FOR ANTISENSE COMPOUND

SBIR FOR PROTEASE ENZYME INHIBITORS

APPOINTMENTS AND ADVANCEMENTS

VERTEX SBIR FOR CRYSTALIZED ENZYMES

ENZON TO CO-DEVELOP CANCER TREATMENT

PROTEIN POLYMER RAISES $9.4M IN IPO

FEVERISH IPO WEEK CLOSES ON TARGET

DEPRENYL BOARD RECOMMENDS STOCK SPLIT

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...